Lexicon Pharmaceuticals Q2 EPS $(0.22) Misses $(0.17) Estimate, Sales $317.00K Beat $70.00K Estimate
Portfolio Pulse from bharat@benzinga.com
Lexicon Pharmaceuticals reported Q2 losses of $(0.22) per share, missing the analyst consensus estimate of $(0.17) by 29.41%. This is a 37.5% decrease over losses from the same period last year. However, the company reported quarterly sales of $317.00K, beating the analyst consensus estimate of $70.00K by 352.86%, a 805.71% increase over sales from the same period last year.
August 04, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lexicon Pharmaceuticals reported a larger than expected loss for Q2 but significantly beat sales estimates.
While the company reported a larger than expected loss, the significant beat on sales estimates could offset the negative impact of the earnings miss. The market reaction could be mixed.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100